

# Nuhad K Ibrahim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1753863/publications.pdf>

Version: 2024-02-01

73  
papers

4,406  
citations

230014

27  
h-index

124990

64  
g-index

73  
all docs

73  
docs citations

73  
times ranked

7191  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Treatment for Smoking on Breast Cancer Patients's Survival. <i>Cancers</i> , 2022, 14, 1464.	1.7	8
2	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	1.7	4
3	Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 46.	2.3	10
4	Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: <scp>MD</scp> Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021, 148, 961-970.	2.3	10
5	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor~positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
6	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e230-e240.	1.9	3
7	Abstract PS15-10: Survival outcomes and prognosis for patients with triple negative breast cancer who received stereotactic radiosurgery for brain metastases. , 2021, , .		0
8	Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. <i>Npj Breast Cancer</i> , 2021, 7, 28.	2.3	2
9	Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. <i>Cancers</i> , 2021, 13, 2050.	1.7	2
10	Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 617874.	1.3	20
11	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2667-2675.	0.8	58
12	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. <i>Oncologist</i> , 2021, 26, e2086-e2089.	1.9	4
13	RADI-17. Outcomes for patients with triple negative breast cancer treated with upfront stereotactic radiosurgery for brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, iii21-iii21.	0.4	0
14	Reply to J. Wei et al. <i>Journal of Clinical Oncology</i> , 2021, , JCO2101973.	0.8	1
15	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. <i>Scientific Reports</i> , 2021, 11, 22242.	1.6	11
16	Phase II study of Radium~223 dichloride combined with hormonal therapy for hormone receptor~positive, bone~dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032.	1.3	19
17	Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. <i>British Journal of Cancer</i> , 2020, 123, 1417-1423.	2.9	5
18	In Reply. <i>Oncologist</i> , 2020, 25, e1252-e1253.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427.	1.9	7
20	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	1.9	520
21	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	3.2	130
22	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019, 120, 1105-1112.	2.9	22
23	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3996-4013.	3.2	77
24	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
25	Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 572-572.	0.8	5
26	Developing anti-HER2 vaccines: Breast cancer experience. <i>International Journal of Cancer</i> , 2018, 143, 2126-2132.	2.3	28
27	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	2.0	11
28	Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2018, 20, 27.	2.2	17
29	MUC1 and Cancer Immunotherapy. , 2018, , 225-240.		5
30	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	2.3	31
31	Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1065-1065.	0.8	6
32	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3006-3006.	0.8	44
33	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	3.4	154
34	Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2017, 22, 526-534.	1.9	11
35	Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 2161-2167.	0.7	30
36	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017, 8, 15916.	5.8	214

#	ARTICLE	IF	CITATIONS
37	Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. <i>Cancer</i> , 2017, 123, 1115-1123.	2.0	28
38	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , 2017, 19, vi40-vi41.	0.6	0
39	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017, 8, 2004-2009.	1.2	14
40	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
41	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 67-77.	1.1	16
42	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
43	Risk stratification in patients with advanced-stage breast cancer by pretreatment [ <sup>18</sup> F]FDG PET/CT. <i>Cancer</i> , 2015, 121, 3965-3974.	2.0	21
44	CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come. <i>Clinical Cancer Research</i> , 2015, 21, 1975-1977.	3.2	2
45	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	3.4	80
46	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 325-331.	1.1	18
47	Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis. <i>Oncologist</i> , 2015, 20, 466-473.	1.9	70
48	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1003-1009.	2.9	28
49	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. <i>Journal of Cancer</i> , 2014, 5, 351-359.	1.2	4
50	Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. <i>Journal of Cancer</i> , 2013, 4, 577-584.	1.2	71
51	Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1092-1100.	1.9	215
52	Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6822-6830.	3.2	63
53	Ixabepilone development across the breast cancer continuum: a paradigm shift. <i>Cancer Management and Research</i> , 2010, 2, 169.	0.9	6
54	Therapeutic Breast Cancer Vaccines. <i>BioDrugs</i> , 2009, 23, 277-287.	2.2	31

#	ARTICLE	IF	CITATIONS
55	Radiologic findings in taxane induced colitis. <i>European Journal of Radiology</i> , 2008, 66, 75-78.	1.2	15
56	Aromatase Inhibitors in Breast Cancer: An Overview. <i>Oncologist</i> , 2006, 11, 553-562.	1.9	110
57	Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. <i>Journal of Clinical Oncology</i> , 2005, 23, 5983-5992.	0.8	383
58	Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6019-6026.	0.8	247
59	Leukemogenic effect of chemotherapy in patients with breast carcinoma. <i>Cancer</i> , 2004, 101, 1479-1481.	2.0	4
60	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. <i>Cancer</i> , 2004, 101, 1508-1513.	2.0	40
61	Clinical Development of the STn-KLH Vaccine (Theratope®). <i>Clinical Breast Cancer</i> , 2003, 3, S139-S143.	1.1	34
62	Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2002, 20, 29-37.	0.6	12
63	Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. <i>Clinical Cancer Research</i> , 2002, 8, 1038-44.	3.2	476
64	Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3407-18.	3.2	105
65	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. <i>Cancer</i> , 2001, 91, 664-671.	2.0	10
66	Phase II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation. <i>Cancer Investigation</i> , 2001, 19, 459-466.	0.6	7
67	Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. <i>Lancet, The</i> , 2000, 355, 281-283.	6.3	125
68	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 471-478.	1.1	51
69	The evolving role of specific estrogen receptor modulators (SERMs). <i>Surgical Oncology</i> , 1999, 8, 103-123.	0.8	23
70	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. , 1999, 86, 1251-1257.		20
71	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	2.6	122
72	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. , 1998, 82, 965-969.		43

#	ARTICLE	IF	CITATIONS
73	New Antiestrogens in Breast Cancer: A Review. Breast Journal, 1998, 4, 213-229.	0.4	3